Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) EBIT (2019 - 2025)

Silo Pharma's EBIT history spans 7 years, with the latest figure at -$1.2 million for Q3 2025.

  • For Q3 2025, EBIT fell 14.0% year-over-year to -$1.2 million; the TTM value through Sep 2025 reached -$1.1 million, up 73.13%, while the annual FY2024 figure was -$488227.0, 87.34% up from the prior year.
  • EBIT for Q3 2025 was -$1.2 million at Silo Pharma, up from -$1.2 million in the prior quarter.
  • Across five years, EBIT topped out at $2.4 million in Q4 2024 and bottomed at -$1.7 million in Q4 2022.
  • The 5-year median for EBIT is -$942416.0 (2021), against an average of -$747892.4.
  • The largest annual shift saw EBIT tumbled 465.48% in 2021 before it surged 306.59% in 2024.
  • A 5-year view of EBIT shows it stood at -$942416.0 in 2021, then plummeted by 75.82% to -$1.7 million in 2022, then grew by 29.77% to -$1.2 million in 2023, then soared by 306.59% to $2.4 million in 2024, then plummeted by 147.9% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for SILO's EBIT are -$1.2 million (Q3 2025), -$1.2 million (Q2 2025), and -$1.1 million (Q1 2025).